Facing the Challenges in Vaccine Upstream Bioprocessing - 5

INTERVIEW

Vaccine Manufacturing
T

he rising prevalence of several diseases and the emergence of several new ones are expected
to encourage the development of novel and effective drugs and vaccines, according to a market
research study by Transparency Market Research. In 2016, the global vaccines market was worth $28
billion and is projected to reach a value of $48 billion by the end of 2025, notes the study. The market
is predicted to register a 6% CAGR between 2017 and 2025.
GEN interviewed Mannan Khambati, of Bharat Serums & Vaccines, India, and George O. Lovrecz, PhD,
adjunct professor of RMIT and Monash University, and Senior Principal Research scientist, CSIRO
Protein Production and Fermentation, Australia, to get a better sense of the manufacturing and
economic issues involved in vaccine development.
GEN: What is currently the most important
production platform for vaccines (eggs, cell
culture plates, roller bottles, stirred-tank
bioreactors)? Do you expect changes in
the upcoming years?
Mr. Khambati: On the basis of the general
trend and a cost/benefit analysis, a cell culture

| GENengnews.com

process utilizing disposable stirred tank or a
perfusion system fits perfectly into the scene.
As the vaccine industry requires high volume
throughput, high yield cell culture along with
a perfusion system should be the preferred
choice in the upcoming years. Disposable perfusion bioreactor systems should take over from
conventional systems to reduce process down-

Mannan Khambati

George O. Lovrecz, PhD

ADDITIONAL CONTENT
Vaccine development and production need
flexible processes, optimized to balance costs
and time-to-market. New technologies such as
single-use equipment and automation open up
new possibilities in upstream bioprocessing.
Learn More

http://www.eppendorf.com/vaccines http://www.eppendorf.com/vaccines http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing